Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2012 2
2013 2
2014 1
2016 2
2019 1
2020 2
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Procoagulant imbalance in patients with non-alcoholic fatty liver disease.
Tripodi A, Fracanzani AL, Primignani M, Chantarangkul V, Clerici M, Mannucci PM, Peyvandi F, Bertelli C, Valenti L, Fargion S. Tripodi A, et al. Among authors: bertelli c. J Hepatol. 2014 Jul;61(1):148-54. doi: 10.1016/j.jhep.2014.03.013. Epub 2014 Mar 18. J Hepatol. 2014. PMID: 24657400
Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades.
Lombardi R, Colavolpe L, Alletto F, Cespiati A, Fatta E, Bertelli C, Cinque F, Pisano G, Pulixi E, Francione P, Maffi G, Iuculano F, Dongiovanni P, Meroni M, Burdick L, Bignamini D, Maggioni M, Valenti L, Fargion S, Fracanzani AL. Lombardi R, et al. Among authors: bertelli c. Dig Liver Dis. 2024 Jan;56(1):144-151. doi: 10.1016/j.dld.2023.07.009. Epub 2023 Jul 26. Dig Liver Dis. 2024. PMID: 37507284
Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP).
Cespiati A, Petta S, Lombardi R, Di Marco V, Calvaruso V, Bertelli C, Pisano G, Fatta E, Sigon G, Iuculano F, Crapanzano L, Gibilaro G, Francione P, Craxì A, Fargion S, Fracanzani AL. Cespiati A, et al. Among authors: bertelli c. Dig Liver Dis. 2021 Oct;53(10):1301-1307. doi: 10.1016/j.dld.2020.11.001. Epub 2020 Nov 17. Dig Liver Dis. 2021. PMID: 33214063
PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma.
Valenti L, Motta BM, Soardo G, Iavarone M, Donati B, Sangiovanni A, Carnelutti A, Dongiovanni P, Rametta R, Bertelli C, Facchetti F, Colombo M, Fargion S, Fracanzani AL. Valenti L, et al. Among authors: bertelli c. PLoS One. 2013 Oct 14;8(10):e75982. doi: 10.1371/journal.pone.0075982. eCollection 2013. PLoS One. 2013. PMID: 24155878 Free PMC article.
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M; PegBeLiver Study Group. Lampertico P, et al. Gut. 2013 Feb;62(2):290-8. doi: 10.1136/gutjnl-2011-301430. Epub 2012 Aug 2. Gut. 2013. PMID: 22859496 Clinical Trial.
Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up.
Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, Norata D, Valenti L, Grigore L, Porzio M, Catapano A, Fargion S. Fracanzani AL, et al. Among authors: bertelli c. Atherosclerosis. 2016 Mar;246:208-13. doi: 10.1016/j.atherosclerosis.2016.01.016. Epub 2016 Jan 12. Atherosclerosis. 2016. PMID: 26803429
12 results